Literature DB >> 19800002

Regulation of aromatase induction by nuclear receptor coregulator PELP1.

Ratna K Vadlamudi1, Rajib Rajhans, Dimple Chakravarty, Binoj C Nair, Sujit S Nair, Dean B Evans, Shiuan Chen, Rajeshwar Rao Tekmal.   

Abstract

Estradiol (E2), estrogen receptor (ER), ER-coregulators have been implicated in the development and progression of breast cancer. In situ E2 synthesis is implicated in tumor cell proliferation through autocrine or paracrine mechanisms, especially in post-menopausal women. Several recent studies demonstrated activity of aromatase P450 (Cyp19), a key enzyme that plays critical role in E2 synthesis in breast tumors. The mechanism by which tumors enhance aromatase expression is not completely understood. Recent studies from our laboratory suggested that PELP1 (Proline, Glutamic acid, Leucine rich Protein 1), a novel ER-coregulator, functions as a potential proto-oncogene and promotes tumor growth in nude mice models without exogenous E2 supplementation. In this study, we found that PELP1 deregulation contributes to increased expression of aromatase, local E2 synthesis and PELP1 cooperates with growth factor signaling components in the activation of aromatase. PELP1 deregulation uniquely up-regulated aromatase expression via activation of aromatase promoter I.3/II. Analysis of PELP1 driven mammary tumors in xenograft as well as in transgenic mouse models revealed increased aromatase expression. PELP1-mediated induction of aromatase requires functional Src and PI3K pathways. Chromatin immuno precipitation (ChIP) assays revealed that PELP1 is recruited to the Aro 1.3/II aromatase promoter. HER2 signaling enhances PELP1 recruitment to the aromatase promoter and PELP1 plays a critical role in HER2-mediated induction of aromatase expression. Mechanistic studies revealed that PELP1 interactions with orphan receptor ERRalpha, and histone demethylases play a role in the activation of aromatase promoter. Accordingly, ChIP analysis showed alterations in histone modifications at the aromatase promoter in the model cells that exhibit local E2 synthesis. Immunohistochemical analysis of breast tumor progression tissue arrays suggested that deregulation of aromatase expression occurs in advanced-stage and node-positive tumors, and that cooverexpression of PELP1 and aromatase occur in a sub set of tumors. Collectively, our results suggest that PELP1 regulation of aromatase represent a novel mechanism for in situ estrogen synthesis leading to tumor proliferation by autocrine loop and open a new avenue for ablating local aromatase activity in breast tumors. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800002      PMCID: PMC2826517          DOI: 10.1016/j.jsbmb.2009.09.009

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  49 in total

Review 1.  The expanding cosmos of nuclear receptor coactivators.

Authors:  David M Lonard; Bert W O'Malley
Journal:  Cell       Date:  2006-05-05       Impact factor: 41.582

2.  NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression.

Authors:  Adam Rosendorff; Shuhei Sakakibara; Sixin Lu; Elliott Kieff; Yan Xuan; Alessandra DiBacco; Yujiang Shi; Yang Shi; Grace Gill
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

Review 3.  Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response.

Authors:  Michael G Rosenfeld; Victoria V Lunyak; Christopher K Glass
Journal:  Genes Dev       Date:  2006-06-01       Impact factor: 11.361

4.  Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade.

Authors:  Chi-Wai Wong; Christopher McNally; Elliot Nickbarg; Barry S Komm; Boris J Cheskis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-01       Impact factor: 11.205

5.  Analysis of aromatase and 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression in deep endometriosis and eutopic endometrium using laser capture microdissection.

Authors:  Sachiko Matsuzaki; Michel Canis; Jean-Luc Pouly; Pierre J Déchelotte; Gérard Mage
Journal:  Fertil Steril       Date:  2006-02       Impact factor: 7.329

6.  HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.

Authors:  Kotha Subbaramaiah; Louise R Howe; Elisa R Port; Edi Brogi; Jack Fishman; Catherine H Liu; Timothy Hla; Clifford Hudis; Andrew J Dannenberg
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

Review 7.  Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription.

Authors:  T N Collingwood; F D Urnov; A P Wolffe
Journal:  J Mol Endocrinol       Date:  1999-12       Impact factor: 5.098

8.  Regulation of aromatase promoter activity in human breast tissue by nuclear receptors.

Authors:  Chun Yang; Bin Yu; Dujin Zhou; Shiuan Chen
Journal:  Oncogene       Date:  2002-04-25       Impact factor: 9.867

9.  ErbB receptor signaling and therapeutic resistance to aromatase inhibitors.

Authors:  Incheol Shin; Todd Miller; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

Review 10.  Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.

Authors:  Anupama E Gururaj; Suresh K Rayala; Ratna K Vadlamudi; Rakesh Kumar
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

View more
  9 in total

Review 1.  Minireview: Deciphering the Cellular Functions of PELP1.

Authors:  Preethi Ravindranathan; Carol A Lange; Ganesh V Raj
Journal:  Mol Endocrinol       Date:  2015-07-09

Review 2.  PELP1: A novel therapeutic target for hormonal cancers.

Authors:  Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  IUBMB Life       Date:  2010-03       Impact factor: 3.885

Review 3.  PELP1: a review of PELP1 interactions, signaling, and biology.

Authors:  Brian J Girard; Andrea R Daniel; Carol A Lange; Julie H Ostrander
Journal:  Mol Cell Endocrinol       Date:  2013-08-08       Impact factor: 4.102

Review 4.  Derailed estrogen signaling and breast cancer: an authentic couple.

Authors:  Bramanandam Manavathi; Oindrilla Dey; Vijay Narsihma Reddy Gajulapalli; Raghavendra Singh Bhatia; Suresh Bugide; Rakesh Kumar
Journal:  Endocr Rev       Date:  2012-09-04       Impact factor: 19.871

5.  Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.

Authors:  Valerie Cortez; Monica Mann; Seshidhar Tekmal; Takayoshi Suzuki; Naoki Miyata; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; Ratna K Vadlamudi
Journal:  Breast Cancer Res       Date:  2012-07-19       Impact factor: 6.466

6.  Cytoplasmic PELP1 and ERRgamma protect human mammary epithelial cells from Tam-induced cell death.

Authors:  Brian J Girard; Tarah M Regan Anderson; Siya Lem Welch; Julie Nicely; Victoria L Seewaldt; Julie H Ostrander
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

Review 7.  Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancer.

Authors:  Enrico Garattini; Marco Bolis; Maurizio Gianni'; Gabriela Paroni; Maddalena Fratelli; Mineko Terao
Journal:  Oncotarget       Date:  2016-07-05

8.  Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy.

Authors:  Zhuan Zhou; Joe X Qiao; Amit Shetty; George Wu; Yi Huang; Nancy E Davidson; Yong Wan
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.207

9.  The ERRα-VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR-CYP24A1-ERRα overexpression correlates with poor prognosis in patients with basal-like breast cancer.

Authors:  Katia Danza; Letizia Porcelli; Simona De Summa; Roberta Di Fonte; Brunella Pilato; Rosanna Lacalamita; Simona Serratì; Amalia Azzariti; Stefania Tommasi
Journal:  Mol Oncol       Date:  2021-07-16       Impact factor: 6.603

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.